|
In a broken health system, greed is winning
Greensboro News & Record Recchi was charged $13,702 for “1 RITUXIMAB INJ 660 MG.” That’s an injection of 660 mg of a cancer wonder drug called Rituxan. The average price paid by all hospitals for this dose is about $4,000, but MD Anderson probably gets a volume discount that … |
|
Novel Chemotherapies More Often Used On- Than Off-Label
Monthly Prescribing Reference … maximize the likelihood of an optimal risk-benefit ratio for both individual patients and the system as a whole.” One author disclosed financial ties to Genentech; a second author is an economic expert for plaintiffs in suit against the … |
|
Global orphan drugs market led by Roche’s rituximab
The Pharma Letter The prize for the top selling drug went to rituximab, an oncology treatment sold by Swiss drug major Roche (ROG: SIX) which sell it under the trade name Rituxan. This drug has present day peak sales value of $7 billion and a discounted peak value of … |
|
B-Cell Transplants for Patients With Rheumatoid Arthritis?
Medscape According to Dr. Lemoine, another interesting point is that after rituximab depletion of B cells, reconstitution favors the B-reg subset. “Who knows if this ‘side effect ‘ is not part of the mechanism of effect of this antibody?” he said. Dr. Flores … |
|
How Hospital Administrators Hide the Umbrella
Daily Beast Recchi was charged $13,702 for “1 RITUXIMAB INJ 660 MG.” That’s an injection of 660 mg of a cancer wonder drug called Rituxan. The average price paid by all hospitals for this dose is about $4,000, but MD Anderson probably gets a volume discount that … |
|
Bendamustine Plus Rituximab Boost PFS in Indolent Lymphomas
Medscape The simple combination of bendamustine plus rituximab (Rituxin) can replace standard therapy in patients newly diagnosed with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma, according to a study published online February 20 in the Lancet. Bendamustine data published in The LancetPharmacy Europe |
MedscapeNational Study: 30% of Chemotherapy Used Off-LabelMedscapeBut the study also turned up some disconcerting findings about the high rate of off-label prescribing of some agents, especially gemcitabine (Gemzar, Lilly), rituximab (Rituxan, Genentec…
Clinical Oncology NewsExpert Commentary: The Future of IbrutinibClinical Oncology NewsIn addition, the US cooperative groups led by the Alliance for Clinical Trials in Oncology are currently planning a randomized study of initial therapy in older patie…
|
Merck, Samsung JV Team Up On Biosimilar Meds
Manufacturing.net The company, based in Whitehouse Station, N.J., has said it’s developing an experimental biosimilar version of rituximab, an antibody-based biologic drug sold under brand names including Rituxan. Samsung Bioepis is a joint venture between Korea’s … |
 TIME |
Bitter Pill: Why Medical Bills Are Killing Us
TIME Recchi was charged $13,702 for “1 RITUXIMAB INJ 660 MG.” That’s an injection of 660 mg of a cancer wonder drug called Rituxan. The average price paid by all hospitals for this dose is about $4,000, but MD Anderson probably gets a volume discount that … |